Objective: To evaluate the safety and efficacy of using TurboHawk atherectomy device in combination with drug-coated balloon (DCB) in treatment of femoropopliteal occlusive diseases. Methods: During April 2016 to October 2017, the treatment of using TurboHawk atherectomy device in combination with DCB was performed in 17 patients with femoropopliteal occlusive diseases. Of the 17 patients, the average age was (66.9±10.5) years; 14 cases were male and 3 cases were female; 13 cases had femoropopliteal stenosis and 4 cases had femoropopliteal occlusion; the preoperative Rutherford classification ranged from 2 to 5 and the preoperative ankle brachial index (ABI) was 0.49+0.18. Doppler ultrasound, CTA or MRA was used to evaluate the patency of target-lesion, postoperatively. Results: Endovascular recanalization of the target lesions were successfully performed in all the 17 patients, of whom, one case with femoral artery perforation underwent salvage covered-stent placement, and one case with distal embolization achieved vascular patency after balloon catheter embolectomy via incision of the femoral artery, and the technical success rate was 88.2%. The postoperative ABI was 0.99±0.27, and it was significantly higher than the preoperative value (P=0.03). The primary patency rate at postoperative 3 and 6 months was 94.1% and 88.2% respectively, and the secondary patency was 100%. Conclusion: Using TurboHawk atherectomy device in combination with DCB is safe and effective in treatment of femoropopliteal occlusive diseases, with favorable short-term results.